On-treatment platelet reactivity through the thromboxane A
Antisense
Cardiovascular disease
Lipoprotein(a)
Oxidized phospholipids
Platelet reactivity
Therapy
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
accepted:
14
04
2023
medline:
13
7
2023
pubmed:
20
6
2023
entrez:
20
6
2023
Statut:
ppublish
Résumé
Pelacarsen decreases plasma levels of lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPL). It was previously reported that pelacarsen does not affect the platelet count. We now report the effect of pelacarsen on on-treatment platelet reactivity. Subjects with established cardiovascular disease and screening Lp(a) levels ≥60 mg per deciliter (~ ≥150 nmol/L) were randomized to receive pelacarsen (20, 40, or 60 mg every 4 weeks; 20 mg every 2 weeks; or 20 mg every week), or placebo for 6-12 months. Aspirin Reaction Units (ARU) and P2Y12 Reaction Units (PRU) were measured at baseline and the primary analysis timepoint (PAT) at 6 months. Of the 286 subjects randomized, 275 had either an ARU or PRU test, 159 (57.8%) were on aspirin alone and 94 (34.2%) subjects were on dual anti-platelet therapy. As expected, the baseline ARU and PRU were suppressed in subjects on aspirin or on dual anti-platelet therapy, respectively. There were no significant differences in baseline ARU in the aspirin groups or in PRU in the dual anti-platelet groups. At the PAT there were no statistically significant differences in ARU in subjects on aspirin or PRU in subjects on dual anti-platelet therapy among any of the pelacarsen groups compared to the pooled placebo group (p > 0.05 for all comparisons). Pelacarsen does not modify on-treatment platelet reactivity through the thromboxane A
Sections du résumé
BACKGROUND
BACKGROUND
Pelacarsen decreases plasma levels of lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPL). It was previously reported that pelacarsen does not affect the platelet count. We now report the effect of pelacarsen on on-treatment platelet reactivity.
METHODS
METHODS
Subjects with established cardiovascular disease and screening Lp(a) levels ≥60 mg per deciliter (~ ≥150 nmol/L) were randomized to receive pelacarsen (20, 40, or 60 mg every 4 weeks; 20 mg every 2 weeks; or 20 mg every week), or placebo for 6-12 months. Aspirin Reaction Units (ARU) and P2Y12 Reaction Units (PRU) were measured at baseline and the primary analysis timepoint (PAT) at 6 months.
RESULTS
RESULTS
Of the 286 subjects randomized, 275 had either an ARU or PRU test, 159 (57.8%) were on aspirin alone and 94 (34.2%) subjects were on dual anti-platelet therapy. As expected, the baseline ARU and PRU were suppressed in subjects on aspirin or on dual anti-platelet therapy, respectively. There were no significant differences in baseline ARU in the aspirin groups or in PRU in the dual anti-platelet groups. At the PAT there were no statistically significant differences in ARU in subjects on aspirin or PRU in subjects on dual anti-platelet therapy among any of the pelacarsen groups compared to the pooled placebo group (p > 0.05 for all comparisons).
CONCLUSION
CONCLUSIONS
Pelacarsen does not modify on-treatment platelet reactivity through the thromboxane A
Identifiants
pubmed: 37338713
doi: 10.1007/s11239-023-02818-6
pii: 10.1007/s11239-023-02818-6
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Clopidogrel
A74586SNO7
Thromboxanes
0
Aspirin
R16CO5Y76E
Purinergic P2Y Receptor Antagonists
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-232Subventions
Organisme : Ionis Pharmaceuticals
ID : Ionis Pharmaceuticals
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Tsimikas S, Fazio S, Ferdinand KC et al (2018) NHLBI Working Group Recommendations to reduce lipoprotein(a)-Mediated risk of Cardiovascular Disease and aortic stenosis. J Am Coll Cardiol 71:177–192
doi: 10.1016/j.jacc.2017.11.014
pubmed: 29325642
pmcid: 5868960
Tsimikas S, Moriarty PM, Stroes ES (2021) Emerging RNA therapeutics to lower blood levels of lp(a): JACC Focus Seminar 2/4. J Am Coll Cardiol 77:1576–1589
doi: 10.1016/j.jacc.2021.01.051
pubmed: 33766265
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I et al (2020) Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 382:244–255
doi: 10.1056/NEJMoa1905239
pubmed: 31893580
O’Donoghue ML, Rosenson RS, Gencer B et al (2022) Small interfering RNA to reduce lipoprotein(a) in Cardiovascular Disease. N Engl J Med 387:1855–1864
doi: 10.1056/NEJMoa2211023
pubmed: 36342163
Nissen SE, Wolski K, Balog C et al (2022) Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA 327:1679–1687
doi: 10.1001/jama.2022.5050
pubmed: 35368052
pmcid: 8978050
Graham MJ, Viney N, Crooke RM, Tsimikas S (2016) Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res 57:340–351
doi: 10.1194/jlr.R052258
pubmed: 26538546
pmcid: 4767000
Viney NJ, van Capelleveen JC, Geary RS et al (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388:2239–2253
doi: 10.1016/S0140-6736(16)31009-1
pubmed: 27665230
Karwatowska-Prokopczuk E, Lesogor A, Yan JH et al (2022) Efficacy and safety of pelacarsen in lowering lp(a) in healthy japanese subjects.J Clin Lipidol
Price MJ, Berger PB, Teirstein PS et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–1105
doi: 10.1001/jama.2011.290
pubmed: 21406646
Gross L, Aradi D, Sibbing D (2016) Platelet function testing in patients on Antiplatelet Medications. Semin Thromb Hemost 42:306–320
doi: 10.1055/s-0035-1570083
pubmed: 26886395
Roe MT, Armstrong PW, Fox KA et al (2012) Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367:1297–1309
doi: 10.1056/NEJMoa1205512
pubmed: 22920930
Crooke ST (2017) Molecular mechanisms of antisense oligonucleotides. Nucleic Acid Ther 27:70–77
doi: 10.1089/nat.2016.0656
pubmed: 28080221
pmcid: 5372764
Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22–31
doi: 10.1056/NEJMoa1716793
pubmed: 29972757
Witztum JL, Gaudet D, Freedman SD et al (2019) Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med 381:531–542
doi: 10.1056/NEJMoa1715944
pubmed: 31390500
Tsimikas S, Viney NJ, Hughes SG et al (2015) Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386:1472–1483
doi: 10.1016/S0140-6736(15)61252-1
pubmed: 26210642
Baker BF, Xia S, Partridge W et al (2023) Integrated Assessment of phase 2 data on GalNAc(3)-Conjugated 2’-O-Methoxyethyl-modified antisense oligonucleotides. Nucleic Acid Ther 33:72–80
doi: 10.1089/nat.2022.0044
pubmed: 36454263
Liu H, Fu D, Luo Y, Peng D (2022) Independent association of lp(a) with platelet reactivity in subjects without statins or antiplatelet agents. Sci Rep 12:16609
doi: 10.1038/s41598-022-21121-7
pubmed: 36198899
pmcid: 9534895
Podrez EA, Byzova TV, Febbraio M et al (2007) Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 13:1086–1095
doi: 10.1038/nm1626
pubmed: 17721545
pmcid: 3042888
Price MJ, Endemann S, Gollapudi RR et al (2008) Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29:992–1000
doi: 10.1093/eurheartj/ehn046
pubmed: 18263931
Michelson AD (2009) Methods for the measurement of platelet function. Am J Cardiol 103:20A–26A
doi: 10.1016/j.amjcard.2008.11.019
pubmed: 19166709
Gurbel PA, Bliden KP, Butler K et al (2010) Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies. The RESPOND Study, Circulation
doi: 10.1161/CIRCULATIONAHA.109.919456
Byun YS, Lee JH, Arsenault BJ et al (2015) Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol 65:1286–1295
doi: 10.1016/j.jacc.2015.01.050
pubmed: 25835440
pmcid: 4386070
Byun YS, Yang X, Bao W et al (2017) Oxidized phospholipids on apolipoprotein B-100 and recurrent ischemic events following stroke or transient ischemic attack. J Am Coll Cardiol 69:147–158
doi: 10.1016/j.jacc.2016.10.057
pubmed: 28081824
McLean JW, Tomlinson JE, Kuang WJ et al (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330:132–137
doi: 10.1038/330132a0
pubmed: 3670400
Gries A, Gries M, Wurm H et al (1996) Lipoprotein(a) inhibits collagen-induced aggregation of thrombocytes. Arterioscler Thromb Vasc Biol 16:648–655
doi: 10.1161/01.ATV.16.5.648
pubmed: 8963722
Barre DE (1998) Lipoprotein (a) reduces platelet aggregation via apo(a)-mediated decreases in thromboxane A(2)production. Platelets 9:93–96
doi: 10.1080/09537109876852
pubmed: 16793682
Rand ML, Sangrar W, Hancock MA et al (1998) Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol 18:1393–1399
doi: 10.1161/01.ATV.18.9.1393
pubmed: 9743227
Zhu P, Tang XF, Song Y et al Association of lipoprotein(a) with platelet aggregation and thrombogenicity in patients undergoing percutaneous coronary intervention.Platelets2020:1–6
Tsironis LD, Mitsios JV, Milionis HJ, Elisaf M, Tselepis AD (2004) Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc Res 63:130–138
doi: 10.1016/j.cardiores.2004.03.005
pubmed: 15194469
Salsoso R, Dalcoquio TF, Furtado RHM et al (2020) Relation of high lipoprotein (a) concentrations to platelet reactivity in individuals with and without coronary artery disease. Adv Ther 37:4568–4584
doi: 10.1007/s12325-020-01483-y
pubmed: 32889667
pmcid: 7547998
Lacaze P, Bakshi A, Riaz M et al (2022) Aspirin for primary Prevention of Cardiovascular events in relation to lipoprotein(a) genotypes. J Am Coll Cardiol 80:1287–1298
doi: 10.1016/j.jacc.2022.07.027
pubmed: 36175048
Dou H, Kotini A, Liu W et al (2021) Oxidized phospholipids promote NETosis and arterial thrombosis in LNK(SH2B3) deficiency. Circulation 144:1940–1954
doi: 10.1161/CIRCULATIONAHA.121.056414
pubmed: 34846914
pmcid: 8663540
Barre DE (2007) Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb/IIIa) receptor. Thromb Res 119:601–607
doi: 10.1016/j.thromres.2006.04.013
pubmed: 16860375
Koltai K, Kesmarky G, Feher G, Tibold A, Toth K (2017) Platelet aggregometry testing: Molecular Mechanisms, Techniques and clinical implications.Int J Mol Sci; 18